This time of year we are concerned with tropical storms and hurricanes. We have learned we all must take special precautions. There is the possibility power and phone service will be disrupted with a storm. Please have at least a 30 day supply of all medications on hand. If you need oxygen or electrical power for medical equipment, please contact the Red Cross Emergency Management about available shelters. If you use a nebulizer, please consider a battery operated or battery backup. There is also a DC inverter which can run a nebulizer from an auto cigarette lighter socket. If our office phones are out due to a storm, emergencies will require you go to the nearest emergency room. Please remember when evacuation orders close our offices, we will open as soon as possible. With two offices, it may be possible for at least one to be open after the storm passes and we have phones and power. Aside from tropical storms, the late summer and fall have plenty of pollen and mold in the air. As school starts, we usually see worsening of indoor allergies in the classroom and transmission of viral and bacterial infections.


We should have the influenza vaccine in September. Medical requires waiting until October 1 or at least 12 months from the last dose for payment. Multiple forms of the vaccine are available. Ask which vaccine is best for you.


Xolair now aprroved down to 6 years of age for Asthma.

ProAir Respiclick now approved down to 4 years of age.


  1. A subcutaneous 20% gammaglobulin study is underway.
  2. Intravenous gammaglobulin studies are underway.
  3. An additional intravenous study will start later this year or early next year.

For further information to become a volunteer for these studies, contact Kelly or Danielle at 561.626.4561 or 561.626.2006.


Dr. Stein has had the following published:

  1. 20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency.
    Ann Allergy Asthma Immunol. 2016 May 25. pii: S1081-1206(16)30181-8. doi: 10.1016/J.anai2016.04.023.
  2. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
    J Clin Immunol. 2016 May 25


Dr. Perez has participated in the follow:

  1. Speaker. Eczema as a sign of Immunodeficiency. Saturday, March 5, 2016. AAAAI, Los Angeles.
  2. Speaker. Newborn Screening for SCID: What every clinician should know. Sunday, March 6, 2016. AAAAI, Los Angeles.
  3. Moderator. Common Variable Immunodeficiency (CVID) from the Bench to the Bedside. Sunday, March 6, 2016. AAAAI, Los Angeles.
  4. Panel Discussion: Interpreting Vaccine Antibody Responses in PIDs. April 14, 2016. Update on Diagnostic Advances in Primary Immunodeficiencies. Clinical Immunology Society.
  5. Speaker. Evaluation of Primary Immunodeficiency. Thursday June 2, 2016. Eastern Allergy Conference, Palm Beach